Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Pralatrexate for Relapsed or Refractory Peripheral T-Cell Lymphomas
NCT03598998Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Feb 2019
- Primary completion
- May 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, pralatrexate in peripheral T-cell lymphoma (PTCL), sponsored by City of Hope. Started Feb 2019; status: active, not recruiting.
02
Drugs
pembrolizumabpralatrexate
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03598998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03598998.